Bruker (NASDAQ:BRKR) Trading 3.9% Higher – Here’s What Happened

Bruker Corporation (NASDAQ:BRKR) shares traded up 3.9% on Tuesday . The stock traded as high as $54.99 and last traded at $54.7180. 291,047 shares were traded during trading, a decline of 88% from the average daily volume of 2,341,848 shares. The stock had previously closed at $52.66.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BRKR shares. Stifel Nicolaus set a $50.00 price objective on Bruker in a research report on Wednesday, August 5th. Wolfe Research began coverage on Bruker in a report on Monday, June 1st. They set a “peer perform” rating on the stock. Zacks Research cut Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. TD Cowen restated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Finally, Barclays lifted their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has an average rating of “Hold” and an average target price of $57.00.

Bruker Stock Up 4.4%

The stock has a market cap of $8.38 billion, a PE ratio of -78.63, a P/E/G ratio of 1.63 and a beta of 1.26. The business has a 50 day moving average of $58.07 and a 200-day moving average of $49.41. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is currently -28.57%.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently made changes to their positions in the business. Sequoia Financial Advisors LLC acquired a new position in Bruker in the 2nd quarter valued at about $250,000. Tidal Investments LLC lifted its position in Bruker by 180.4% during the 2nd quarter. Tidal Investments LLC now owns 29,092 shares of the medical research company’s stock worth $1,751,000 after acquiring an additional 18,715 shares during the period. WINTON GROUP Ltd acquired a new stake in Bruker during the 2nd quarter worth approximately $344,000. Engineers Gate Manager LP grew its stake in shares of Bruker by 141.8% in the 2nd quarter. Engineers Gate Manager LP now owns 56,825 shares of the medical research company’s stock valued at $3,420,000 after purchasing an additional 33,329 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Bruker in the second quarter valued at approximately $445,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.